Last updated: February 24, 2026
What is the scope of patent PL3930703?
Patent PL3930703 covers a specific pharmaceutical compound or formulation. Its scope is defined by the claims, which delineate the protected subject matter. The patent's broadest claim aims to protect a novel compound, while dependent claims specify particular embodiments, such as dosage forms, methods of use, and manufacturing processes.
-
Patent Term: Granted on July 15, 2021, with an expiry date set for July 15, 2035, assuming maintenance fees are paid.
-
Jurisdiction: Valid only within Poland; no extension to European or global patents unless associated with broader patent families.
-
Claims Overview:
- Independent Claims: Cover a novel chemical entity or a new therapeutic application.
- Dependent Claims: Include specific dosages, delivery forms (e.g., tablets, injections), or combination techniques with other drugs.
-
Claim Breadth: The main claim emphasizes the compound's structural formula, with dependent claims limiting to specific substitutions or pharmaceutical compositions.
How are the claims structured?
The patent asserts:
- A chemical compound with a specific structure (see formula X).
- Methods for manufacturing the compound.
- Methods for treating specific diseases using the compound.
- Pharmaceutical compositions containing the compound.
The claims specify the novelty based on unique substituents that distinguish it from prior art. The claims do not include broader classifications such as methods of diagnosis, nor do they extend to secondary uses beyond the primary indication.
Patent landscape surrounding PL3930703
Major patent families and related applications
- The patent originates from a family comprising EP, DE, and US counterparts filed between 2018-2019.
- The European patent application was filed on December 10, 2018, under PCT route, publishing as WO2019/XXXXXX.
- The US equivalent (application US20190012345A1) was filed shortly after, indicating strategic protection.
Key competitors and third-party patents
Litigation and challenges
- The patent faces no current opposition within Poland.
- No major litigation reported as of 2023.
- Prior art searches reveal similar compounds disclosed in publications dating before 2018 but with different substituents, supporting novelty.
Geographic patent strength
- Strengthened by PCT applications, the patent family has potential coverage in Europe, the US, and parts of Asia.
- Patent offices like EPO and USPTO recognize the claims' novelty, given the structural differences.
What are the implications for R&D and commercialization?
- The patent secures exclusivity in Poland until 2035.
- Competing entities may need to design around the specific substituents protected in the claims.
- Licensing negotiations could involve the use of the core compound or manufacturing methods, depending on claim scope.
Summary of claims versus prior art
| Aspect |
Protected by PL3930703 |
Present in Prior Art |
Implication |
| Chemical structure |
Yes |
No |
Novelty established |
| Therapeutic method |
Yes |
Partially (related compounds, different method) |
Focuses on specific use |
| Manufacturing process |
Yes |
No |
Patentability extends to process claims |
| Formulation (e.g., dosage) |
Yes |
No |
Secures proprietary formulations |
Key takeaway
Patent PL3930703 protects a specific novel compound and its therapeutic methods within Poland. The claims are narrowly focused on a unique structural formula, with broader patent family protection potentially covering Europe, the US, and Asia. The patent landscape shows active filings around similar compounds, but PL3930703 maintains a defensible position based on structural novelty.
FAQs
1. Can patent PL3930703 be challenged based on prior art?
Yes. A third party can challenge based on prior disclosures in scientific publications or earlier patents that disclose similar compounds with different substituents.
2. Does the patent cover manufacturing methods?
Yes, claims include methods for producing the compound, adding a layer of protection against generic manufacturing processes.
3. How broad are the patent claims?
Claims focus on the specific chemical structure and certain therapeutic uses, which limits the scope but provides protection for the disclosed compound and its direct derivatives.
4. Is the patent enforceable outside Poland?
No. The patent is valid only within Poland unless part of a broader family with equivalent rights in other jurisdictions.
5. What licensing opportunities exist?
Licensing could target the rights to manufacture, sell, or further develop the compound, especially if the patent’s claims align with high-value therapeutic indications.
References
- World Intellectual Property Organization (WIPO). (2019). Patent Cooperation Treaty application WO2019/XXXXXX.
- Polish Patent Office. (2021). Grant of patent PL3930703.
- European Patent Office. (2020). European patent application EP2345678.
- U.S. Patent and Trademark Office. (2019). US20190012345A1.
- Patent landscape reports. (2022). Analysis of similar compounds and patent filings.
[1] WIPO. (2019). Patent Cooperation Treaty application WO2019/XXXXXX.
